期刊文献+

在不含酒精的脂肪肝疾病和尖锐 ischemic 击严厉和结果之间的协会 被引量:2

Association between nonalcoholic fatty liver disease and acute ischemic stroke severity and outcome
下载PDF
导出
摘要 AIM:To evaluate the association of nonalcoholic fatty liver disease(NAFLD)with acute ischemic stroke severity and in-hospital outcome.METHODS:We prospectively studied all patients who were admitted in our Department with acute ischemic stroke between September 2010 and August 2012(n=415;39.5%males,mean age 78.8±6.6 years).The severity of stroke was assessed with the National Institutes of Health Stroke Scale(NIHSS)score at admission.NALFD was defined as serum alanine aminotransferase and/or aspartate aminotransferase levels above the upper limit of normal in the absence of other causes of elevated aminotransferases levels[chronic hepatitis B or C,drug toxicity,increased alcohol consumption(】21 and】14 drinks per week in men and women,respectively),cholestatic diseases or rhabdomyolysis].The outcome was assessed with the modified Rankin scale(mRS)score at discharge and in-hospital mortality.Adverse outcome was defined as mRS score at discharge≥2.Dependency at discharge was defined as mRS score between 2 to 5.RESULTS:NAFLD was present in 7.7%of the study population.Patients with NAFLD had lower serum high-density lipoprotein cholesterol and higher triglyceride levels than patients without NAFLD(P【0.05 for both comparisons).Demographic data,the prevalence of other cardiovascular risk factors and the prevalence of established CVD did not differ between the two groups.At admission,the NIHSS score did not differ between patients with and without NAFLD(6.3±6.4and 8.8±9.6,respectively;P=NS).At discharge,the mRS score did not differ between the two groups(1.9±2.2 and 2.6±2.2 in patients with and without NAFLD,respectively;P=NS).Rates of dependency at discharge were also similar in patients with and without NAFLD(36.8%and 55.0%,respectively;P=NS)as were the rates of adverse outcome(42.9%and58.6%,respectively;P=NS).In-hospital mortality rates also did not differ between the 2 groups(8.0%and 7.0%in patients with and without NAFLD,respectively;P=NS).CONCLUSION:The presence of NAFLD in patients admitted for acute ischemic stroke does not appear to be associated with more severe stroke or with worse in-hospital outcome. AIM:To evaluate the association of nonalcoholic fatty liver disease(NAFLD)with acute ischemic stroke severity and in-hospital outcome.METHODS:We prospectively studied all patients who were admitted in our Department with acute ischemic stroke between September 2010 and August 2012(n=415;39.5%males,mean age 78.8±6.6 years).The severity of stroke was assessed with the National Institutes of Health Stroke Scale(NIHSS)score at admission.NALFD was defined as serum alanine aminotransferase and/or aspartate aminotransferase levels above the upper limit of normal in the absence of other causes of elevated aminotransferases levels[chronic hepatitis B or C,drug toxicity,increased alcohol consumption(>21 and>14 drinks per week in men and women,respectively),cholestatic diseases or rhabdomyolysis].The outcome was assessed with the modified Rankin scale(mRS)score at discharge and in-hospital mortality.Adverse outcome was defined as mRS score at discharge≥2.Dependency at discharge was defined as mRS score between 2 to 5.RESULTS:NAFLD was present in 7.7%of the study population.Patients with NAFLD had lower serum high-density lipoprotein cholesterol and higher triglyceride levels than patients without NAFLD(P<0.05 for both comparisons).Demographic data,the prevalence of other cardiovascular risk factors and the prevalence of established CVD did not differ between the two groups.At admission,the NIHSS score did not differ between patients with and without NAFLD(6.3±6.4and 8.8±9.6,respectively;P=NS).At discharge,the mRS score did not differ between the two groups(1.9±2.2 and 2.6±2.2 in patients with and without NAFLD,respectively;P=NS).Rates of dependency at discharge were also similar in patients with and without NAFLD(36.8%and 55.0%,respectively;P=NS)as were the rates of adverse outcome(42.9%and58.6%,respectively;P=NS).In-hospital mortality rates also did not differ between the 2 groups(8.0%and 7.0%in patients with and without NAFLD,respectively;P=NS).CONCLUSION:The presence of NAFLD in patients admitted for acute ischemic stroke does not appear to be associated with more severe stroke or with worse in-hospital outcome.
出处 《World Journal of Hepatology》 CAS 2013年第11期621-626,共6页 世界肝病学杂志(英文版)(电子版)
关键词 NONALCOHOLIC fatty liver DISEASE Stroke Outcome AMINOTRANSFERASES γ-glutamyl TRANSPEPTIDASE CARDIOVASCULAR DISEASE Type 2 diabetes MELLITUS Obesity CARDIOVASCULAR risk Nonalcoholic fatty liver disease Stroke Outcome Aminotransferases γ-glutamyl transpeptidase Cardiovascular disease Type 2 diabetes mellitus Obesity Cardiovascular risk
  • 相关文献

参考文献16

  • 1Alan S. Go,Dariush Mozaffarian,Véronique L. Roger,Emelia J. Benjamin,Jarett D. Berry,William B. Borden,Dawn M. Bravata,Shifan Dai,Earl S. Ford,Caroline S. Fox,Sheila Franco,Heather J. Fullerton,Cathleen Gillespie,Susan M. Hailpern,John A. Heit,Virginia J. Howard,Mark D. Huffman,Brett M. Kissela,Steven J. Kittner,Daniel T. Lackland,Judith H. Lichtman,Lynda D. Lisabeth,David Magid,Gregory M. Marcus,Ariane Marelli,David B. Matchar,Darren K. McGuire,Emile R. Mohler,Claudia S. Moy,Mi.Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association[J]. Circulation . 2013 (1)
  • 2Naga Chalasani,Zobair Younossi,Joel E. Lavine,Anna Mae Diehl,Elizabeth M. Brunt,Kenneth Cusi,Michael Charlton,Arun J. Sanyal.The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology[J]. Gastroenterology . 2012 (7)
  • 3Konstantinos Tziomalos,Vassilios G. Athyros,Asterios Karagiannis.Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options[J]. Current Vascular Pharmacology . 2012 (2)
  • 4Zobair M. Younossi,Maria Stepanova,Mariam Afendy,Yun Fang,Youssef Younossi,Hesham Mir,Manirath Srishord.Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008[J]. Clinical Gastroenterology and Hepatology . 2011 (6)
  • 5Christopher D. Williams,Joel Stengel,Michael I. Asike,Dawn M. Torres,Janet Shaw,Maricela Contreras,Cristy L. Landt,Stephen A. Harrison.Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study[J]. Gastroenterology . 2011 (1)
  • 6Ivan Ying,Gustavo Saposnik,Marian J. Vermeulen,Andrew Leung,Joel G. Ray.Nonalcoholic Fatty Liver Disease and Acute Ischemic Stroke[J]. Epidemiology . 2011 (1)
  • 7Konstantinos Tziomalos,Vasilios G Athyros,Asterios Karagiannis,Dimitri P Mikhailidis.The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification[J]. Current Opinion in Cardiology . 2010 (4)
  • 8Apostolos I. Hatzitolios,Triandafillos P. Didangelos,Anestis T. Zantidis,Konstantinos Tziomalos,George A. Giannakoulas,Dimitrios T. Karamitsos.Diabetes mellitus and cerebrovascular disease: which are the actual data?[J]. Journal of Diabetes and Its Complications . 2009 (4)
  • 9Constance E. Ruhl,James E. Everhart.Elevated Serum Alanine Aminotransferase and γ-Glutamyltransferase and Mortality in the United States Population[J]. Gastroenterology . 2009 (2)
  • 10Silvia Sookoian,Carlos J. Pirola.Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review[J]. Journal of Hepatology . 2008 (4)

共引文献7

同被引文献31

  • 1Paschalis Paschos,Konstantinos Tziomalos.不含酒精的脂肪肝疾病和高血压蛋白原酶血管收缩素系统: 为治疗的含意[J].World Journal of Hepatology,2012,4(12):327-331. 被引量:12
  • 2Stella D Bouziana,Konstantinos Tziomalos.Inhibition of apoptosis in the management of nonalcoholic fatty liver disease[J].World Journal of Gastrointestinal Pharmacology and Therapeutics,2013,4(1):4-8. 被引量:5
  • 3Alberico L. Catapano,?eljko Reiner,Guy De Backer,Ian Graham,Marja-Riitta Taskinen,Olov Wiklund,Stefan Agewall,Eduardo Alegria,M. John Chapman,Paul Durrington,Serap Erdine,Julian Halcox,Richard Hobbs,John Kjekshus,Pasquale Perrone Filardi,Gabriele Riccardi,Robert F. Storey,David Wood.ESC/EAS Guidelines for the management of dyslipidaemias[J]. Atherosclerosis . 2011 (1)
  • 4Mitsuhiro Yokoyama,Hideki Origasa,Masunori Matsuzaki,Yuji Matsuzawa,Yasushi Saito,Yuichi Ishikawa,Shinichi Oikawa,Jun Sasaki,Hitoshi Hishida,Hiroshige Itakura,Toru Kita,Akira Kitabatake,Noriaki Nakaya,Toshiie Sakata,Kazuyuki Shimada,Kunio Shirato.Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis[J]. The Lancet . 2007 (9567)
  • 5Yuki Kimura,Hideyuki Hyogo,Sho-ichi Yamagishi,Masayoshi Takeuchi,Tomokazu Ishitobi,Yoshitaka Nabeshima,Koji Arihiro,Kazuaki Chayama.Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH[J]. Journal of Gastroenterology . 2010 (7)
  • 6Vasilios G Athyros,Konstantinos Tziomalos,Thomas D Gossios,Theodora Griva,Panagiotis Anagnostis,Konstantinos Kargiotis,Efstathios D Pagourelias,Eleni Theocharidou,Asterios Karagiannis,Dimitri P Mikhailidis.Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis[J]. The Lancet . 2010 (9756)
  • 7Hideyuki Hyogo,Susumu Tazuma,Koji Arihiro,Keiko Iwamoto,Yoshitaka Nabeshima,Motoki Inoue,Tomokazu Ishitobi,Michihiro Nonaka,Kazuaki Chayama.Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia[J]. Metabolism . 2008 (12)
  • 8C. Fernández-Miranda,M. Pérez-Carreras,F. Colina,G. López-Alonso,C. Vargas,J.A. Solís-Herruzo.A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease[J]. Digestive and Liver Disease . 2007 (3)
  • 9Konstantinos Tziomalos,Vassilios G. Athyros,Asterios Karagiannis.Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options[J]. Current Vascular Pharmacology . 2012 (2)
  • 10Zobair M. Younossi,Maria Stepanova,Mariam Afendy,Yun Fang,Youssef Younossi,Hesham Mir,Manirath Srishord.Changes in the Prevalence of the Most Common Causes of Chronic Liver Diseases in the United States From 1988 to 2008[J]. Clinical Gastroenterology and Hepatology . 2011 (6)

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部